Publications of Y. Genzel

Kalbfuss, B., Wolff, M. W., Genzel, Y., Zimmermann, A., Best, C., Morenweiser, R., & Reichl, U.A generic purification scheme for the production of human influenza vaccines derived from serum-free mammalian cell culturePresented at: Vaccine TechnologyPuerto Vallarta, Mexico, June 25, 2006.

Kalbfuss, B., Wolff, M. W., Genzel, Y., Zimmermann, A., Morenweiser, R., & Reichl, U.Chromatography-based purification of influenza A virus for the production of human whole-virion vaccinesPresented at: ISPPP 2006 : 26th International Symposium on the Separation of Proteins, Peptides and PolynucleotidesInnsbruck, Austria, October 17, 2006.

Ritter, J. B., Genzel, Y., & Reichl, U.Monitoring Energy Metabolism: The Challenge of Intracellular Metabolite Analysis of Mammalian Cells in CulturePresented at: 1st Max Planck Workshop on "Metabolomics"Magdeburg, Germany, April 4, 2006.

Schulze-Horsel, J., Bock, A., Genzel, Y., & Reichl, U.Mammalian cell culture for influenza vaccine production: physiology during cell growth and virus propagation phasePresented at: GVC/DECHEMA-Jahrestagungen 2006 mit 24. DECHEMA-Jahrestagung der BiotechnologenWiesbaden, Germany, September 24, 2006.

Genzel, Y., Schulze-Horsel, J., Möhler, L., Sidorenko, Y., & Reichl, U.Influenza Vaccines: Challenges in Mammalian Cell Culture TechnologyPresented at: 19th ESACT MeetingHarrogate, UK, June 5, 2005.

Genzel, Y., König, S., & Reichl, U.Amino acid analysis in mammalian cell culture based virus vaccine production processesPresented at: IICS : 17th annual International Ion Chromatography SymposiumTrier, Germany, September 20, 2004.

Dogra, T., Pelz, L., Rüdiger, D., Hein, M. D., Baelkner, M., Julia D. Boehme, J. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccinationPresented at: 32^nd Annual Meeting of the Society for Virology (GfV)Ulm (Germany), March 28, 2023.

Dogra, T., Pelz, L., Rüdiger, D., Hein, M. D., Baelkner, M., Julia D. Boehme, J. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccinationPresented at: 8^th European Congress of VirologyGdańsk (Poland), May 4, 2023.

Küchler, J., Opitz, P., Kupke, S. Y., Genzel, Y., Benndorf, D., & Reichl, U.Absolute quantification of viral proteins during single-round replication of vaccine producer cell linesPresented at: 32^nd Annual Meeting of the Society for Virology (GfV) Ulm (Germany), March 28, 2023.

Küchler, J., Opitz, P., Kupke, S. Y., Genzel, Y., Benndorf, D., & Reichl, U.Absolute quantification of influenza A virus proteins during single-round replication in vaccine producer cell linesPresented at: 16^th PEACe (Protein Expression in Animal Cells) ConferenceSitges (Spain), September 24, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Hein, M. D., Marichal-Gallardo, P., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivoPresented at: Cell Culture Engineering (CCE) XVIII Cancun (Mexico), April 23, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Marichal-Gallardo, P., Hein, M. D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo StudiesPresented at: Himmelfahrtstagung on Bioprocess Engineering 2023Weimar (Germany), May 15, 2023.

Pelz, L., Dogra, T., Boehme, J. D., Marichal-Gallardo, P., Hein, M. D., Genzel, Y., Bruder, D., Kupke, S. Y., & Reichl, U.Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral EfficacyPresented at: 32^nd Annual Meeting of the Society for Virology (GFV)Ulm (Germany), March 25, 2023.

Göbel, S., Dorn, M., Jaén Chavez, K., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processesPresented at: Vaccine Technology VIIISitges (Spain), June 12, 2022.

Göbel, S., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Towards the production of a fusogenic oncolytic rVSV-NDV virus in perfusion modePresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Göbel, S., Kortum, F., Jaén Chavez, K., Jordan, I., Sandig, V., Altomonte, J., Genzel, Y., & Reichl, U.Production of a fusogenic oncolytic VSV-NDV virus: cell-line screening and process development in small-scale suspension culturesPresented at: Advancing Manufacture of Cell and Gene Therapies VIICoronado, CA (USA), February 6, 2022.

Hein, M., Chawla, A., Arora , P., Cattaneo, M., Winkler, M., Pöhlmann, S., Genzel, Y., Kupke, S. Y., & Reichl, U.Production of influenza A virus-derived defective interfering particles for antiviral therapy in a high cell density perfusion cultivationPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.

Küchler, J., Püttker, S., Lahmann, P., Genzel, Y., Kupke, S. Y., Benndorf, D., & Reichl, U.Absolute quantification of viral proteins during single-round replication of MDCK suspension cellsPresented at: Proteomic Forum 2022Leipzig (Germany), April 3, 2022.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. G., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U.Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral CandidatesPresented at: Vaccine Technology VIIISitges (Spain), June 12, 2022.

Pelz, L., Rüdiger, D., Dogra, T., Alnaji, F. G., Genzel, Y., Brooke, C. B., Kupke, S. Y., & Reichl, U.Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidatesPresented at: 27th ESACT MeetingLisbon (Portugal), June 26, 2022.